Home > Healthcare & Medical Devices > Hospital-acquired Infection Control Market
Hospital-Acquired Infection Control Market size is expected to grow commendably from 2022 to 2028, given the rising ageing population and the high rate of inpatient stay among patients with diabetes worldwide. In addition, the significant increase in surgical procedures in countries including the United States will further augment the implementation of hospital-acquired infection control measures, as HAIs are associated with the use of unclean medical equipment and devices. HAI refers to an infection developed among patients during the course of treatment within the healthcare setting. Hospital-acquired infection prevention and control programs demand a basic understanding of the epidemiology of the diseases, various risk factors that increase susceptibility to the infection, as well as the treatment procedures that may result in infections.
Increasing prevalence of chronic diseases and disabilities among senior citizens across the European Union is a key factor bolstering the global hospital-acquired infection control market trends through 2028. As per the CDC, around 1.7 million patients acquire HAIs every year, which could lead to the mounting use of disposable or single-use medical products to reduce infection acquired due to prolonged hospital stay. This factor, along with the outbreak of bacterial and fungal infections across hospital settings in major cities of the United States, is also anticipated to generate opportunities for market growth during the forecast timeline.
With regards to product, the hospital-acquired infection control market from the disinfectants segment will amass hefty profits by 2028. Segment growth is led by the growing usage of chemical compounds such as hypochlorite to disinfect contaminated medical devices to alleviate the global burden of HAIs. In 2021, the WHO highlighted the urgent need to ensure hand hygiene and other infection control measures across both high- and low-income countries in the global survey on the implementation of national infection prevention and control programs. This strong focus on infection control will proliferate the deployment of hand disinfectants across hospitals and in turn, propel market expansion from this segment over the coming years.
The Middle East and Africa is poised to emerge as a lucrative revenue prospect for the hospital-acquired infection control market till 2028. This is a result of the rising burden of CVDs, high healthcare spending, and the growing number of private hospitals in countries like Saudi Arabia. Furthermore, the prevalence of diseases like Ebola in South Africa could amplify the rate of hospitalization and in turn, boost the need for preventative measures against hospital-acquired infections across the region.
The competitive landscape of the global market comprises companies such as Ecolab, Cepheid (Danaher Corporation), 3M, Abbott, F. Hoffmann-La Roche Ltd., Belimed (Metall Zug), Steris plc, Getinge AB, Medivators Inc. (Cantel Medical Corporation), and Olympus. These companies are focusing on new service launches, partnerships, and acquisitions to expand their business footprint in the global market. For instance, in September 2021, Sodexo extended its partnership with Ecolab for the control of hospital-acquired infections under the Protecta Plus program in the U.S. This program was designed to reduce the infection risk across hospitals and healthcare facilities with the use of the Bioquell hydrogen peroxide vapor technology of Ecolab.
The deadly coronavirus pandemic has posed unprecedented impacts on healthcare settings across the globe. As the pandemic persisted and surged across America, hospitals and other healthcare systems in the region witnessed historic challenges due to financial pressures caused by the slowdown of regular operations for non-emergency care. However, severe implications associated with COVID-19, such as hospitalization, may help the hospital-acquired infection control industry gain momentum in the coming years. Critically ill patients diagnosed with COVID-19 are at high-risk for hospital-acquired infections. Furthermore, according to research led by Dr Jonathan Read from Lancaster University, over one in ten of COVID-19 patients in the UK caught the disease in the hospital. This, in turn, could amplify the demand for hospital-acquired infection control measures considerably over the years ahead.
Market, by Product
Market, by End-use
The above information is provided for the following regions and countries: